AbbVie Inc. (NYSE:ABBV) Q4 2023 Earnings Conference Call February 2, 2024 9:00 AM ET
Company Participants
Liz Shea - Vice President of Investor Relations
Rick Gonzalez - Chairman of the Board & Chief Executive Officer
Rob Michael - President & Chief Operating Officer
Jeff Stewart - Executive Vice President & Chief Commercial Officer
Carrie Strom - Senior Vice President, AbbVie and President, Global Allergan Aesthetics
Roopal Thakkar - SVP, Development & Regulatory Affairs & Chief Medical Officer
Scott Reents - Executive Vice President & Chief Financer
Tom Hudson - Senior Vice President, R&D & Chief Scientific Officer
Conference Call Participants
Chris Schott - JPMorgan
Terence Flynn - Morgan Stanley
Andrew Baum - Citigroup
Mohit Bansal - Wells Fargo
Carter Gould - Barclays
Gary Nachman - Raymond James
Steve Scala - TD Cowen
Tim Anderson - Wolfe Research
Tim Lugo - William Blair
James Shin - Deutsche Bank
David Risinger - Leerink Partners
Luisa Hector - Berenberg
Operator
Good morning, and thank you for standing by. Welcome to the AbbVie Fourth Quarter 2023 Earnings Conference Call. All participants will be able to listen-only until the question-and-answer portion of this call. [Operator Instructions] Today's call is also being recorded. If you have any objection, you may disconnect at this time.
I would now like to introduce Ms. Liz Shea, Senior Vice President, Investor Relations. Thank you. You may begin.
Liz Shea
Good morning, and thanks for joining us. Also on the call with me today are Rick Gonzalez, Chairman of the Board and Chief Executive Officer; Rob Michael, President and Chief Operating Officer; Jeff Stewart, Executive Vice President, Chief Commercial Officer; Scott Reents, Executive Vice President, Chief Financial Officer; Carrie Strom, Senior Vice President, AbbVie and President, Global Allergan Aesthetics; and Roopal Thakkar, Senior Vice President, Chief Medical Officer, Global Therapeutics. Joining us for the Q&A portion of the call is Tom Hudson, Senior Vice President, Chief Scientific Officer, Global Research.
Before we get started, I'll note that some statements we make today may be considered forward-looking statements based on our current expectations. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in our forward-looking statements. Additional information about these risks and uncertainties is included in our SEC filings. AbbVie undertakes no obligation to update these forward-looking statements except as required by law.
On today's conference call, non-GAAP financial measures will be used to help investors understand AbbVie's business performance. These non-GAAP financial measures are reconciled with comparable GAAP financial measures in our earnings release and regulatory filings from today, which can be found on our website. In addition to the news release issued this morning, we have also posted slides on our website at investors.abbvie.com that supplement some of the content we'll be covering this morning. Following our prepared remarks, we'll take your questions.